In an effort to establish itself as a leading CNS drug development company, Biotie Therapies has agreed to acquire Synosia Therapeutics in an all-share deal valued at €93.6 M (US$121 M). The combined company will have nine clinical-stage CNS drug candidates, an international presence with operations in Finland, the US and Switzerland and a strengthened financial position.